Punicalagin |
رقم الكتالوجGN10047
One-Click Copy Product Info
|
Punicalagin is a ellagitannin, a phenolic compound with antioxidant, anti-inflammatory and anticancer effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 65995-63-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Punicalagin is a ellagitannin, a phenolic compound with antioxidant, anti-inflammatory and anticancer effects[1, 2]. Punicalagin is a reversible and non-competitive 3-chymotrypsin-like protease (3CLpro) inhibitor that inhibits SARS-CoV-2 replication in vitro[3].
In vitro, PC-3, LNCaP, and BPH-1 cells were treated with Punicalagin (10, 50, 100µM) for 24h. Punicalagin inhibited the viability of PC-3 and LNCaP cells in a dose-dependent manner, but had no significant effect on the viability of BPH-1 cells. Punicalagin (100µM) increased the expression of enrichment factors in PC-3 and LNCaP cells[4]. Punicalagin (12.5-100μM) treatment of thyroid cancer cell line BCPAP cells for 24h-48h inhibited cell viability in a time- and dose-dependent manner and increased the number of autophagic vacuoles (AVO) in cells, but did not induce apoptosis[5].
In vivo, Punicalagin (50mg/kg) was intraperitoneally injected into mice with collagen-induced arthritis (CIA) for 14 days, which reduced the severity of arthritis and bone destruction in mice and decreased serum IL-6 and TNF-α levels[6]. Punicalagin (25, 50, 100mg/kg) was orally administered to pregnant rats with L-NAME-induced preeclampsia (PE) for 7 days, which significantly reduced diastolic blood pressure, systolic blood pressure and mean arterial pressure, restored angiogenesis balance, and enhanced placental antioxidant capacity[7].
References:
[1] Venusova E, Kolesarova A, Horky P, et al. Physiological and immune functions of punicalagin[J]. Nutrients, 2021, 13(7): 2150.
[2] Rozadi N, Oktavia S, Fauziah F. Pharmacological Activities of Punicalagin: A Review[J]. Journal of Drug Delivery and Therapeutics, 2022, 12(2): 148-155.
[3] Du R, Cooper L, Chen Z, et al. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro[J]. Antiviral research, 2021, 190: 105075.
[4] Adaramoye O, Erguen B, Nitzsche B, et al. Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells[J]. Chemico-biological interactions, 2017, 274: 100-106.
[5] Cheng X, Gao Y, Yao X, et al. Punicalagin induces apoptosis-independent autophagic cell death in human papillary thyroid carcinoma BCPAP cells[J]. RSC advances, 2016, 6(72): 68485-68493.
[6] Huang M, Wu K, Zeng S, et al. Punicalagin inhibited inflammation and migration of fibroblast-like synoviocytes through NF-κB pathway in the experimental study of rheumatoid arthritis[J]. Journal of inflammation research, 2021: 1901-1913.
[7] Wang Y, Huang M, Yang X, et al. Supplementing punicalagin reduces oxidative stress markers and restores angiogenic balance in a rat model of pregnancy-induced hypertension[J]. The Korean journal of physiology & pharmacology, 2018, 22(4): 409-417.
| Cell experiment [1]: | |
|
Cell lines |
PC-3, LNCaP, BPH-1 cells |
|
Preparation Method |
PC-3, LNCaP and BPH-1 cells were cultured in a 96-well microtiter plate containing 0.1mL of RPMI growth media/well for 24h. Cells were incubated with Punicalagin dissolved in DMSO, and Punicalagin concentrations of 10, 50 and 100µM were used with incubation period of 24-96h. Cells were evaluated for their viability using the XTT assay. |
|
Reaction Conditions |
10, 50, 100µM; 24h |
|
Applications |
Punicalagin concentration-dependently inhibited viability in PC-3 and LNCaP cells, while viability in BPH-1 cells was insignificantly affected. |
| Animal experiment [2]: | |
|
Animal models |
DBA/1 mice |
|
Preparation Method |
DBA/1 mice (male, 8–9 weeks) were intradermally injected at the tail base with 200mg of bovine type II collagen emulsified at a 1:1 ratio (vol/vol) in Freund's complete adjuvant (day 0), and then boosted 21 days later using bovine type II collagen emulsified at a 1:1 ratio in incomplete Freund's adjuvant (day 21). Mice were randomly treated daily by intraperitoneal injection of DMSO (n=8) or Punicalagin (50mg/kg/day, n=8) for 14 days, which was initiated on the second day of booster immunization (day 22). Set up a normal control group including 8 mice without any treatment. Hindlimb samples were collected and fixed in 10% formalin for 48h. After a series of dehydration, waxing, and embedding, the joints were cut into 5µm thick sections for subsequent analysis. |
|
Dosage form |
50mg/kg/day for 14 days; i.p. |
|
Applications |
Punicalagin alleviated arthritis severity and bone destruction, and decreased serum IL-6 and TNF-α in collagen-induced arthritis (CIA) mice. |
|
References: |
|
| Cas No. | 65995-63-3 | SDF | |
| Canonical SMILES | O=C1OC2=C(C3=C(C(C(C(OC[C@H]4OC5O)=O)=CC(O)=C6O)=C6O)C(O)=C2O)C(C1=C(C(C(O)=C7O)=C(C=C7O)C(O[C@H]4[C@@H]([C@H]5OC8=O)OC(C(C(C(C(O)=C9O)=C8C=C9O)=C%10O)=CC(O)=C%10O)=O)=O)C(O)=C%11O)=C%11OC3=O | ||
| Formula | C48H28O30 | M.Wt | 1084.72 |
| الذوبان | ≥ 108.4mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 921.9 μL | 4.6095 mL | 9.219 mL |
| 5 mM | 184.4 μL | 921.9 μL | 1.8438 mL |
| 10 mM | 92.2 μL | 460.9 μL | 921.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)